Skip to content
Peptide research

Vesilute

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A dipeptide bioregulator (Glu-Asp) marketed for bladder and prostate health, meant to normalize detrusor muscle function and reduce urinary tract inflammation. The case is almost entirely speculative: claims for overactive bladder and prostate symptoms rest on limited mechanistic work, with no independent human validation. There is essentially no human safety data, and supply is unregulated research-grade. Not FDA-approved; contraindicated in pregnancy.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Normalization of detrusor contractility and bladder smooth muscle function

    Speculative

    One 1993 animal study tested a related prostate extract, not this specific dipeptide; mechanism-based only.

  • Improvement of overactive bladder symptoms in women with detrusor overactivity

    Speculative

    No published clinical trials or registered studies support this specific claim.

  • Tissue-specific gene expression regulation via epigenetic DNA interaction

    Low

    Multiple studies show short peptides of this class binding DNA and altering transcription in cells.

Evidence limits

Evidence Level
Very Limited Evidence

The clinical evidence for Vesilute is extremely limited and relies substantially on studies of the related polypeptide extract Vezusten rather than the isolated Glu-Asp dipeptide. Human evidence cited here concerns Vezusten, not isolated Vesilute, and includes a 2022 placebo-controlled randomized trial as well as the 2024 cohort of 20 women with overactive bladder treated with intramuscular Vezusten injections, showing statistically significant improvements in urination frequency (14 to 11 per day, p<0.001), urge incontinence episodes (p=0.004), and maximum cystometric capacity (267 to 320 ml). Preclinical evidence demonstrates normalization of detrusor contractility in rat models with infravesical obstruction. The mechanistic rationale draws on the broader Khavinson short peptide framework, where dipeptides are shown to regulate gene expression through DNA interaction. Major limitations: the 2024 cohort was not randomized and was very small (n=20), the human studies used Vezusten (polypeptide extract) rather than the isolated Vesilute dipeptide, all research originates from Russian institutions, and no independent validation exists.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Extremely limited clinical evidence and lack of independent validation

    High
  • Unproven efficacy of the isolated dipeptide vs. polypeptide extract

    High
  • Unregulated product quality (research-grade sources)

    High
  • Contraindicated in pregnancy and lactation

    Moderate
  • Possible mild side effects (theoretical and vendor-reported)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.